29809-14-1

Usage

InChI:InChI=1/C10H11NO2/c12-11(13)10-7-3-5-8-4-1-2-6-9(8)10/h3,5,7H,1-2,4,6H2

Upstream product

• 119-64-2 tetralin 
• 7664-93-9 sulfuric acid 
• 90-15-3 α-naphthol 

Downstream Products

• 86-57-7 1-Nitronaphthalene 
• 51114-73-9 5-nitro-1-tetralone 
• 2217-41-6 1-amino-5,6,7,8-tetrahydronaphthalene 
• 603-11-2 3-nitrophthalic acid 
• 112534-15-3 (2-carboxy-6-nitro-phenyl)-glyoxylic acid 
• 112534-27-7 (2-carboxy-3-nitro-phenyl)-glyoxylic acid 
• 826-67-5 1,3,4,5-tetrahydrobenz[c,d]indole 
• 19356-99-1 N-(5,6,7,8-tetrahydro-[1]naphthyl)-phthalamic acid 
• 40153-45-5 N-(4-nitro-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 
• 41823-28-3 5-amino-3,4-dihydronaphthalen-1(2H)-one 
• 57536-84-2 1-(5-tetralinyl)piperazine 
• 58161-31-2 8-nitro-3,4-dihydro-1(2H)naphthalenone 
• 2217-43-8 6-amino-1,2,3,4-tetrahydronaphthalene 

Relevant academic research and scientific papers

HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF

Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.

Novel sulfamoyl benzamides as selective CB2 agonists with improved in vitro metabolic stability

A lead optimization campaign in our previously reported sulfamoyl benzamide class of CB2 agonists was conducted to improve the in vitro metabolic stability profile in this series while retaining high potency and selectivity for the CB2 receptor. From this study, compound 14, N-(3,4-dimethyl-5-(morpholinosulfonyl)phenyl)-2,2-dimethylbutanamide, was identified as a potent and selective CB2 agonist exhibiting moderate in vitro metabolic stability and oral bioavailability. Compound 14 demonstrated in vivo efficacy in a rat model of post-surgical pain.

Conformationally constrained analogues of N′-(4-tert-butylbenzyl)-N-(4-methylsulfonylaminobenzyl)thiourea as TRPV1 antagonists

A series of bicyclic analogues having indan and tetrahydronaphthalene templates in the A-region were designed as conformationally constrained analogues of our previously reported potent TRPV1 antagonists (1, 3). The activities for rat TRPV1 of the conformationally restricted analogues were moderately or markedly diminished, particularly in the case of the tetrahydronaphthalene analogues. The analysis indicated that steric constraints at the benzylic position in the bicyclic analogues may be an important factor for their unfavorable interaction with the receptor.